The National Cancer Institute (NCI) is soliciting grant applications for the early-stage development of innovative molecular and cellular analysis technologies to enhance basic and clinical cancer research. The funding opportunity, part of the NCI's Innovative Molecular Analysis Technologies (IMAT) Program, aims to support highly innovative technologies that can improve the targeting, probing, or assessment of molecular and cellular features of cancer biology. Applicants may include a wide range of organizations such as higher education institutions, nonprofits, small businesses, and government entities. Key requirements include demonstrating the potential to accelerate or enhance cancer research, including areas like early detection, diagnosis, treatment, and epidemiology, as well as the ability to address cancer health disparities.
The R61 grant mechanism will be used for this funding opportunity, which has a deadline of October 3, 2025. Award amounts have typically ranged from approximately $200,000 to over $1.6 million in total costs, with project periods spanning 2-5 years. The work must be conducted at the applicant's facilities within the United States, though some international collaboration may be allowed, particularly for clinical trial networks.
Generated 12/18/24, 6:13 AM